Table 1. Effects of different treatment regimens on PROs in patients with moderately active RA (MITT; LOCF)
| Parameter | Adjusted Mean Changea (SE), Wks 36–88 | ||
|---|---|---|---|
| E50/M (n=201) | E25/M (n=201) | P/M (n=197) | |
| HAQ total score | 0.05* (0.03) | 0.10* (0.03) | 0.37 (0.03) |
| EQ-5D total index | –0.03* | –0.04* | –0.14 |
| WPAI % activity impairment due to RA | 3.54* (1.42) | 4.26* (1.43) | 14.55 (1.44) |
| Endpoint | % Patients Achieving Endpointb, Wks 0–88 | ||
| HAQ total score Δ ≥0.22 | 72.4* | 72.5* | 51.0 |
| EQ-5D total index Δ ≥0.05 | 73.4* | 67.0† | 53.1 |
*p<0.0001, E50/M and E25/M vs P/M; †p<0.01, E25/M vs P/M. aANCOVA, with wk 36 baseline, treatment, geographic region, and wk 36 DAS28 strata as predictors; bCMH test, stratified by wk 36 DAS28 strata and region.